Shopping Cart 0
Cart Subtotal
USD 0

Natco Pharma Ltd (NATCOPHARM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Natco Pharma Ltd (Natco Pharma) focuses on the research, development, manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage forms in capsule, injection and tablet. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn's disease, hypertension, Myelodysplastic syndrome and prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) for the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.

Natco Pharma Ltd (NATCOPHARM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Natco Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Panacea Biotec Enters into Agreement with Natco Pharma and Breckenridge Pharma 12

Licensing Agreements 13

Natco Pharma Enters into Licensing Agreement with Gilead Sciences 13

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 14

Equity Offering 15

Natco Pharma Plans to Raise up to USD232 Million in Public Offering of Shares 15

Natco Pharma Raises USD54.5 Million in Private Placement of Shares 16

Natco Pharma Completes Private Placement Of Shares For USD 18 Million 17

Debt Offering 18

Natco Pharma Plans Private Placement Of Debentures For USD 24.3 Million 18

Acquisition 19

Kotak Private Equity Sells 1.18% Stake In Natco Pharma 19

Natco Pharma Acquires 51% Stake In Natco Organics From Tamilnadu Industrial Development 20

Natco Pharma Ltd-Key Competitors 21

Natco Pharma Ltd-Key Employees 22

Natco Pharma Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Joint Venture 24

Recent Developments 25

Financial Announcements 25

Nov 05, 2018: NATCO records INR 583.40 Crores consolidated revenue and INR 181.50 crore of profit, after tax, for the second quarter, FY 2018-19 25

Aug 08, 2018: NATCO records INR 574.5 Crores consolidated revenue and INR 181.1 Crore of profit, after tax, for the First Quarter, FY2018-19 26

May 23, 2018: NATCO records INR 2,242 Crore consolidated revenue and INR 695 Crore of profit, after tax, for the full year ended March 2018 27

Feb 06, 2018: NATCO records INR 573.6 Crore revenue and INR 217.4 Crore of Profit, after tax, for the Third Quarter, FY 2017-18 28

Aug 07, 2017: NATCO Pharma Reports Financial Results For The Quarter Ended 30 June 2017 29

May 30, 2017: NATCO records INR 2078.9 Crore total consolidated revenue and INR 486.0 Crore of profit, after tax, for the full year ended March 2017 30

Feb 14, 2017: NATCO records INR 685.13 Crore total consolidated revenue and INR 194.76 Crore of profit, after tax, for the Third Quarter, FY 2017 14 February 2017 31

Corporate Communications 32

Aug 07, 2017: Natco Pharma Announces Resignation of Directors 32

Legal and Regulatory 33

Feb 17, 2018: USFDA completes inspection of Natco's Mekaguda API facility with zero observations 33

Jul 20, 2017: NATCO receives establishment inspection report (EIR) from U.S. food and drug administration (FDA) 34

Jan 25, 2017: NATCO updates on USFDA inspection at its Kothur Formulation Facility 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36


List Of Figure

List of Figures

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Natco Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Natco Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Panacea Biotec Enters into Agreement with Natco Pharma and Breckenridge Pharma 12

Natco Pharma Enters into Licensing Agreement with Gilead Sciences 13

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 14

Natco Pharma Plans to Raise up to USD232 Million in Public Offering of Shares 15

Natco Pharma Raises USD54.5 Million in Private Placement of Shares 16

Natco Pharma Completes Private Placement Of Shares For USD 18 Million 17

Natco Pharma Plans Private Placement Of Debentures For USD 24.3 Million 18

Kotak Private Equity Sells 1.18% Stake In Natco Pharma 19

Natco Pharma Acquires 51% Stake In Natco Organics From Tamilnadu Industrial Development 20

Natco Pharma Ltd, Key Competitors 21

Natco Pharma Ltd, Key Employees 22

Natco Pharma Ltd, Other Locations 23

Natco Pharma Ltd, Subsidiaries 23

Natco Pharma Ltd, Joint Venture 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Natco Pharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Natco Pharma Ltd (Natco Pharma) focuses on the research, development, manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage forms in capsule, injection and tablet. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn's disease, hypertension, Myelodysplastic syndrome and prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) for the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.

Natco Pharma Ltd (NATCOPHARM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Natco Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Panacea Biotec Enters into Agreement with Natco Pharma and Breckenridge Pharma 12

Licensing Agreements 13

Natco Pharma Enters into Licensing Agreement with Gilead Sciences 13

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 14

Equity Offering 15

Natco Pharma Plans to Raise up to USD232 Million in Public Offering of Shares 15

Natco Pharma Raises USD54.5 Million in Private Placement of Shares 16

Natco Pharma Completes Private Placement Of Shares For USD 18 Million 17

Debt Offering 18

Natco Pharma Plans Private Placement Of Debentures For USD 24.3 Million 18

Acquisition 19

Kotak Private Equity Sells 1.18% Stake In Natco Pharma 19

Natco Pharma Acquires 51% Stake In Natco Organics From Tamilnadu Industrial Development 20

Natco Pharma Ltd-Key Competitors 21

Natco Pharma Ltd-Key Employees 22

Natco Pharma Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Joint Venture 24

Recent Developments 25

Financial Announcements 25

Nov 05, 2018: NATCO records INR 583.40 Crores consolidated revenue and INR 181.50 crore of profit, after tax, for the second quarter, FY 2018-19 25

Aug 08, 2018: NATCO records INR 574.5 Crores consolidated revenue and INR 181.1 Crore of profit, after tax, for the First Quarter, FY2018-19 26

May 23, 2018: NATCO records INR 2,242 Crore consolidated revenue and INR 695 Crore of profit, after tax, for the full year ended March 2018 27

Feb 06, 2018: NATCO records INR 573.6 Crore revenue and INR 217.4 Crore of Profit, after tax, for the Third Quarter, FY 2017-18 28

Aug 07, 2017: NATCO Pharma Reports Financial Results For The Quarter Ended 30 June 2017 29

May 30, 2017: NATCO records INR 2078.9 Crore total consolidated revenue and INR 486.0 Crore of profit, after tax, for the full year ended March 2017 30

Feb 14, 2017: NATCO records INR 685.13 Crore total consolidated revenue and INR 194.76 Crore of profit, after tax, for the Third Quarter, FY 2017 14 February 2017 31

Corporate Communications 32

Aug 07, 2017: Natco Pharma Announces Resignation of Directors 32

Legal and Regulatory 33

Feb 17, 2018: USFDA completes inspection of Natco's Mekaguda API facility with zero observations 33

Jul 20, 2017: NATCO receives establishment inspection report (EIR) from U.S. food and drug administration (FDA) 34

Jan 25, 2017: NATCO updates on USFDA inspection at its Kothur Formulation Facility 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36


List Of Figure

List of Figures

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Natco Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Natco Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Panacea Biotec Enters into Agreement with Natco Pharma and Breckenridge Pharma 12

Natco Pharma Enters into Licensing Agreement with Gilead Sciences 13

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 14

Natco Pharma Plans to Raise up to USD232 Million in Public Offering of Shares 15

Natco Pharma Raises USD54.5 Million in Private Placement of Shares 16

Natco Pharma Completes Private Placement Of Shares For USD 18 Million 17

Natco Pharma Plans Private Placement Of Debentures For USD 24.3 Million 18

Kotak Private Equity Sells 1.18% Stake In Natco Pharma 19

Natco Pharma Acquires 51% Stake In Natco Organics From Tamilnadu Industrial Development 20

Natco Pharma Ltd, Key Competitors 21

Natco Pharma Ltd, Key Employees 22

Natco Pharma Ltd, Other Locations 23

Natco Pharma Ltd, Subsidiaries 23

Natco Pharma Ltd, Joint Venture 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Natco Pharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.